Cargando…

Phase II Study of Modified Carboplatin Plus Weekly Nab‐Paclitaxel in Elderly Patients with Non‐Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1301

LESSONS LEARNED. Weekly nanoparticle albumin‐bound‐paclitaxel (75 mg/m(2)) in combination with carboplatin (area under the curve 6 mg/mL/min) in elderly patients with previously untreated, advanced non‐small cell lung cancer showed favorable efficacy, was well tolerated, and showed less neuropathic...

Descripción completa

Detalles Bibliográficos
Autores principales: Miyauchi, Eisaku, Inoue, Akira, Usui, Kazuhiro, Sugawara, Shunichi, Maemondo, Makoto, Saito, Heisuke, Fujita, Yuka, Kato, Terufumi, Suzuki, Toshiro, Harada, Toshiyuki, Watanabe, Hiroshi, Nakagawa, Taku, Ichinose, Masakazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5469596/
https://www.ncbi.nlm.nih.gov/pubmed/28526722
http://dx.doi.org/10.1634/theoncologist.2017-0059
_version_ 1783243606932324352
author Miyauchi, Eisaku
Inoue, Akira
Usui, Kazuhiro
Sugawara, Shunichi
Maemondo, Makoto
Saito, Heisuke
Fujita, Yuka
Kato, Terufumi
Suzuki, Toshiro
Harada, Toshiyuki
Watanabe, Hiroshi
Nakagawa, Taku
Ichinose, Masakazu
author_facet Miyauchi, Eisaku
Inoue, Akira
Usui, Kazuhiro
Sugawara, Shunichi
Maemondo, Makoto
Saito, Heisuke
Fujita, Yuka
Kato, Terufumi
Suzuki, Toshiro
Harada, Toshiyuki
Watanabe, Hiroshi
Nakagawa, Taku
Ichinose, Masakazu
author_sort Miyauchi, Eisaku
collection PubMed
description LESSONS LEARNED. Weekly nanoparticle albumin‐bound‐paclitaxel (75 mg/m(2)) in combination with carboplatin (area under the curve 6 mg/mL/min) in elderly patients with previously untreated, advanced non‐small cell lung cancer showed favorable efficacy, was well tolerated, and showed less neuropathic toxicity. This modified regimen offers potential for the treatment of elderly patients. BACKGROUND. The CA031 trial suggested weekly nanoparticle albumin‐bound‐paclitaxel (nab‐PTX) was superior in efficacy to paclitaxel (PTX) once every 3 weeks when combined with carboplatin (CBDCA) for advanced non‐small cell lung cancer (NSCLC) patients; a subgroup analysis of elderly patients looked promising. In a multicenter phase II trial, we prospectively evaluated the efficacy and tolerability of modified CBDCA plus weekly nab‐PTX for elderly patients with untreated advanced NSCLC. METHODS. Eligible patients received CBDCA (area under the curve [AUC] 6 mg/mL/min) on day 1 and nab‐PTX (75 mg/m(2)) on days 1, 8, and 15 every 4 weeks. The primary endpoint was an overall response rate (ORR), and secondary endpoints were progression‐free survival (PFS), overall survival (OS), and toxicity. RESULTS. Of 32 patients (median age of 78 years), 84% were male, 56% had stage IV NSCLC, and 56% had squamous cell carcinoma. ORR and disease control rates were 50% (95% confidence interval (CI): 33–67) and 94% (95% CI: 85–100), respectively. Median PFS and OS were 6.4 months (95% CI: 4.8–8.0) and 17.5 months (95% CI: 11.9–23.1), respectively. Grade ≥3 toxicities were neutropenia (47%), leukopenia (38%), anemia (34%), thrombocytopenia (25%), and anorexia (9%). Febrile neutropenia and treatment‐related deaths were not observed. CONCLUSION. Modified CBDCA plus weekly nab‐PTX demonstrated significant efficacy and acceptable toxicities in elderly patients with advanced NSCLC.
format Online
Article
Text
id pubmed-5469596
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher AlphaMed Press
record_format MEDLINE/PubMed
spelling pubmed-54695962017-07-13 Phase II Study of Modified Carboplatin Plus Weekly Nab‐Paclitaxel in Elderly Patients with Non‐Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1301 Miyauchi, Eisaku Inoue, Akira Usui, Kazuhiro Sugawara, Shunichi Maemondo, Makoto Saito, Heisuke Fujita, Yuka Kato, Terufumi Suzuki, Toshiro Harada, Toshiyuki Watanabe, Hiroshi Nakagawa, Taku Ichinose, Masakazu Oncologist Clinical Trial Results LESSONS LEARNED. Weekly nanoparticle albumin‐bound‐paclitaxel (75 mg/m(2)) in combination with carboplatin (area under the curve 6 mg/mL/min) in elderly patients with previously untreated, advanced non‐small cell lung cancer showed favorable efficacy, was well tolerated, and showed less neuropathic toxicity. This modified regimen offers potential for the treatment of elderly patients. BACKGROUND. The CA031 trial suggested weekly nanoparticle albumin‐bound‐paclitaxel (nab‐PTX) was superior in efficacy to paclitaxel (PTX) once every 3 weeks when combined with carboplatin (CBDCA) for advanced non‐small cell lung cancer (NSCLC) patients; a subgroup analysis of elderly patients looked promising. In a multicenter phase II trial, we prospectively evaluated the efficacy and tolerability of modified CBDCA plus weekly nab‐PTX for elderly patients with untreated advanced NSCLC. METHODS. Eligible patients received CBDCA (area under the curve [AUC] 6 mg/mL/min) on day 1 and nab‐PTX (75 mg/m(2)) on days 1, 8, and 15 every 4 weeks. The primary endpoint was an overall response rate (ORR), and secondary endpoints were progression‐free survival (PFS), overall survival (OS), and toxicity. RESULTS. Of 32 patients (median age of 78 years), 84% were male, 56% had stage IV NSCLC, and 56% had squamous cell carcinoma. ORR and disease control rates were 50% (95% confidence interval (CI): 33–67) and 94% (95% CI: 85–100), respectively. Median PFS and OS were 6.4 months (95% CI: 4.8–8.0) and 17.5 months (95% CI: 11.9–23.1), respectively. Grade ≥3 toxicities were neutropenia (47%), leukopenia (38%), anemia (34%), thrombocytopenia (25%), and anorexia (9%). Febrile neutropenia and treatment‐related deaths were not observed. CONCLUSION. Modified CBDCA plus weekly nab‐PTX demonstrated significant efficacy and acceptable toxicities in elderly patients with advanced NSCLC. AlphaMed Press 2017-05-19 2017-06 /pmc/articles/PMC5469596/ /pubmed/28526722 http://dx.doi.org/10.1634/theoncologist.2017-0059 Text en © AlphaMed Press; the data published online to support this summary is the property of the authors.
spellingShingle Clinical Trial Results
Miyauchi, Eisaku
Inoue, Akira
Usui, Kazuhiro
Sugawara, Shunichi
Maemondo, Makoto
Saito, Heisuke
Fujita, Yuka
Kato, Terufumi
Suzuki, Toshiro
Harada, Toshiyuki
Watanabe, Hiroshi
Nakagawa, Taku
Ichinose, Masakazu
Phase II Study of Modified Carboplatin Plus Weekly Nab‐Paclitaxel in Elderly Patients with Non‐Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1301
title Phase II Study of Modified Carboplatin Plus Weekly Nab‐Paclitaxel in Elderly Patients with Non‐Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1301
title_full Phase II Study of Modified Carboplatin Plus Weekly Nab‐Paclitaxel in Elderly Patients with Non‐Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1301
title_fullStr Phase II Study of Modified Carboplatin Plus Weekly Nab‐Paclitaxel in Elderly Patients with Non‐Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1301
title_full_unstemmed Phase II Study of Modified Carboplatin Plus Weekly Nab‐Paclitaxel in Elderly Patients with Non‐Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1301
title_short Phase II Study of Modified Carboplatin Plus Weekly Nab‐Paclitaxel in Elderly Patients with Non‐Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1301
title_sort phase ii study of modified carboplatin plus weekly nab‐paclitaxel in elderly patients with non‐small cell lung cancer: north japan lung cancer study group trial 1301
topic Clinical Trial Results
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5469596/
https://www.ncbi.nlm.nih.gov/pubmed/28526722
http://dx.doi.org/10.1634/theoncologist.2017-0059
work_keys_str_mv AT miyauchieisaku phaseiistudyofmodifiedcarboplatinplusweeklynabpaclitaxelinelderlypatientswithnonsmallcelllungcancernorthjapanlungcancerstudygrouptrial1301
AT inoueakira phaseiistudyofmodifiedcarboplatinplusweeklynabpaclitaxelinelderlypatientswithnonsmallcelllungcancernorthjapanlungcancerstudygrouptrial1301
AT usuikazuhiro phaseiistudyofmodifiedcarboplatinplusweeklynabpaclitaxelinelderlypatientswithnonsmallcelllungcancernorthjapanlungcancerstudygrouptrial1301
AT sugawarashunichi phaseiistudyofmodifiedcarboplatinplusweeklynabpaclitaxelinelderlypatientswithnonsmallcelllungcancernorthjapanlungcancerstudygrouptrial1301
AT maemondomakoto phaseiistudyofmodifiedcarboplatinplusweeklynabpaclitaxelinelderlypatientswithnonsmallcelllungcancernorthjapanlungcancerstudygrouptrial1301
AT saitoheisuke phaseiistudyofmodifiedcarboplatinplusweeklynabpaclitaxelinelderlypatientswithnonsmallcelllungcancernorthjapanlungcancerstudygrouptrial1301
AT fujitayuka phaseiistudyofmodifiedcarboplatinplusweeklynabpaclitaxelinelderlypatientswithnonsmallcelllungcancernorthjapanlungcancerstudygrouptrial1301
AT katoterufumi phaseiistudyofmodifiedcarboplatinplusweeklynabpaclitaxelinelderlypatientswithnonsmallcelllungcancernorthjapanlungcancerstudygrouptrial1301
AT suzukitoshiro phaseiistudyofmodifiedcarboplatinplusweeklynabpaclitaxelinelderlypatientswithnonsmallcelllungcancernorthjapanlungcancerstudygrouptrial1301
AT haradatoshiyuki phaseiistudyofmodifiedcarboplatinplusweeklynabpaclitaxelinelderlypatientswithnonsmallcelllungcancernorthjapanlungcancerstudygrouptrial1301
AT watanabehiroshi phaseiistudyofmodifiedcarboplatinplusweeklynabpaclitaxelinelderlypatientswithnonsmallcelllungcancernorthjapanlungcancerstudygrouptrial1301
AT nakagawataku phaseiistudyofmodifiedcarboplatinplusweeklynabpaclitaxelinelderlypatientswithnonsmallcelllungcancernorthjapanlungcancerstudygrouptrial1301
AT ichinosemasakazu phaseiistudyofmodifiedcarboplatinplusweeklynabpaclitaxelinelderlypatientswithnonsmallcelllungcancernorthjapanlungcancerstudygrouptrial1301